Bactiguard
Bactiguard is a Swedish medical technology company that licenses its proprietary noble metal alloy coating (BIP) to global MedTech partners such as Becton Dickinson and Zimmer Biomet to prevent infections on catheters, endotracheal tubes, and implants, and also sells HYDROCYN aqua wound care products through regional distributors.
- Company typePublic
- Founded2005
- HeadquartersTullinge, Sweden
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bactiguard does
Bactiguard is a Swedish medical technology company founded in 2005 and listed on Nasdaq Stockholm (BACTI-B) that develops and licenses a proprietary infection-prevention coating called Bactiguard Infection Protection (BIP). The BIP technology is an ultra-thin noble metal alloy coating applied to medical device surfaces; when the coated device contacts bodily fluids, the noble metals create a galvanic effect that reduces microbial adhesion and prevents biofilm formation without releasing active substances into the patient. The technology has been clinically validated in over 40 publications covering more than 100,000 patients, with documented reductions of 69% in catheter-associated urinary tract infections (CAUTI) and 53% in ventilator-associated pneumonia (VAP), and more than 200 million coated devices have been used globally with no reported adverse events tied to the coating.
The company's primary business model is B2B licensing: Bactiguard partners with leading global medical device companies such as Becton Dickinson (Foley catheters, expanded in May 2026) and Zimmer Biomet (ZNN Bactiguard trauma nail, restructured December 2025) under multi-year contracts that include application development fees, exclusivity payments, and ongoing royalties once partner products reach market. Bactiguard also sells a wound management portfolio directly via regional distributors, most notably HYDROCYN aqua (a hypochlorous acid-based solution and gel for chronic and acute wounds) and surgical sutures, with recent geographic expansion through CDSCO approval in India. The model generates revenue across development, exclusivity, and full-license phases, and is supplemented by direct wound-care product sales.
Bactiguard's headcount sits between 101 and 250 employees, with headquarters in Stockholm and operational offices in Tullinge, Sweden. The leadership team is led by CEO Christine Lind, with Stefan Grass as Chief Medical Officer and Deputy CEO and Patrick Bach as CFO. The company is covered by analysts at SEB, Carnegie, and Kepler Cheuvreux. Operating geographies span Europe, North America, Asia Pacific (including India, China, and Malaysia), the Middle East (UAE), and Latin America (Ecuador, Peru). Reported nine-month 2025 revenue of SEK 163.2 million is down 15.7% year-over-year, although EBITDA remains positive at SEK 19.1 million for the same period following the company's first EBITDA-profitable year in 2024.
Bactiguard firmographics
Firmographics- Name
- Bactiguard
- Legal name
- Bactiguard Holding AB (publ)
- Website
- https://bactiguard.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Bactiguard is a Swedish medical technology company that licenses its proprietary noble metal alloy coating (BIP) to global MedTech partners such as Becton Dickinson and Zimmer Biomet to prevent infections on catheters, endotracheal tubes, and implants, and also sells HYDROCYN aqua wound care products through regional distributors.
- Ownership category
- akta.pro rank
Bactiguard industry classification
Industry- Product category
- Medical Device Infection Prevention
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)
Keywords
Where Bactiguard is headquartered
LocationHeadquarters
- HQ city
- Tullinge
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Bactiguard business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- License Partnerships - Application Development: Revenues generated during close collaboration with partners' R&D teams to explore application of infection prevention technology to underlying medical devices. Development work is confidential to protect competitive advantages.
- License Partnerships - Exclusivity: Revenue from granting exclusive rights to apply the coating technology to certain medical devices. Partners may not yet have products in market due to pending regulatory approvals.
- License Partnerships - Full License: Variable remuneration (royalties) once license partners' products reach the market and are sold in specified regions or globally. This represents ongoing recurring revenue as products commercialize.
- Wound Management Products: Direct sales of wound care products including HYDROCYN aqua (solution and gel) and surgical sutures through selected local distributors.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B License Partnership Model |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Bactiguard product offering
Product offeringCore offering
Bactiguard develops and licenses its proprietary Bactiguard Infection Protection (BIP) technology—an ultra-thin noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices through a galvanic effect—to global MedTech partners for integration into their branded devices including Foley catheters, central venous catheters, endotracheal tubes, and orthopedic trauma implants. The company also distributes a wound management portfolio (HYDROCYN aqua hypochlorous acid wound care products and surgical sutures) through regional distributors to healthcare providers.
Product overview
Bactiguard operates a dual-product business model: (1) a license-focused platform offering its proprietary Bactiguard Infection Protection (BIP) technology—a noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices—which is integrated into partner MedTech companies' products including Foley catheters (standard and silicone variants), Foley TempSensor, Central Venous Catheters, Endotracheal Tubes (standard and Evac variants), and ZNN trauma nails; and (2) a proprietary Wound Management portfolio comprising HYDROCYN aqua (hypochlorous acid-based wound care solution) and surgical sutures, distributed through local distributors.
Differentiator
Problem solved
Functional benefit
Brands
- BIP (Bactiguard Infection Protection): The company's proprietary noble metal alloy coating technology applied to medical devices to prevent microbial adhesion and biofilm formation
- HYDROCYN aqua
Products and services
- Bactiguard Infection Protection (BIP) Technology Core proprietary technology consisting of an ultra-thin noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices through a galvanic effect when in contact with fluids. Licensed to MedTech partners for integration into their branded devices.
- BIP Foley Catheter Urinary catheter with Bactiguard's infection prevention coating, intended for patients catheterized longer than two days to reduce catheter-associated urinary tract infections (CAUTI). Demonstrated 69% reduction in CAUTI in clinical studies.
- BIP Foley Catheter – Silicone Silicone-based version of the BIP Foley Catheter offering the same infection prevention properties with a different material composition for patients with specific material compatibility requirements.
- BIP Foley TempSensor Foley catheter with integrated temperature sensor for continuous patient temperature monitoring during intensive care, combined with Bactiguard's infection prevention coating.
- BIP Central Venous Catheter Central venous catheter with Bactiguard coating designed to reduce catheter-related bloodstream infections (CRBSI) in intensive care settings.
- BIP Endotracheal Tube Endotracheal tube with Bactiguard coating to reduce microbial adhesion and ventilator-associated pneumonia (VAP) risk in mechanically ventilated patients.
- BIP Endotracheal Tube Evac Advanced endotracheal tube combining subglottic secretion drainage with Bactiguard's infection prevention coating, demonstrated to reduce VAP by 53% in the VITAL study published in Annals of Intensive Care.
- ZNN Bactiguard Trauma nail system with Bactiguard coating for orthopedic applications, commercialized through license partnership with Zimmer Biomet outside the US for fracture fixation with infection prevention.
- HYDROCYN aqua Advanced wound care portfolio containing hypochlorous acid (HOCl) for wound cleansing, debridement, and irrigation of chronic and acute wounds, supporting healing and infection prevention. Available as solution and gel. Distributed through selected local distributors.
- Surgical Sutures Range of surgical sutures offered as part of Bactiguard's wound management portfolio, sold through selected local distributors in various regions.
Quantifiable outcome
- 69% reduction in catheter-associated urinary tract infections (CAUTI)
- +3 more outcomes
Companies that use Bactiguard
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Bactiguard technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Bactiguard partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, minor and strategic.
- Becton DickinsoncoreGlobal licensing partnership for infection-prevention catheter technologies. Becton Dickinson licenses Bactiguard's coating technology for application to Foley catheters and other infection prevention products sold globally under the BD brand. The partnership was strengthened in 2026 to expand access to Foley catheters designed to reduce infection risk for patients worldwide.
- Zimmer BiometcoreUpdated trauma license agreement for commercialization of ZNN Bactiguard coated trauma nail system outside the US. The revised deal gives Zimmer Biomet non-exclusive rights in specific regions, with Bactiguard regaining global rights and receiving royalties and fixed fees.
- European Bone and Joint Infection Society (EBJIS)minorBactiguard joined Zimmer Biomet at EBJIS conference in Barcelona to showcase the ZNN Bactiguard technology and demonstrate how the infection prevention coating works in orthopedic applications.
- Karolinska Institute and Umeå UniversitystrategicCollaboration on HAI Proactive project funded by Swedish Innovation Agency Vinnova, focused on reducing healthcare-associated infections through new technology. Project stakeholders include Karolinska University Hospital, Umeå University Hospital, Region Stockholm, Region Västernorrland, and Bactiguard.
- King's College Hospital LondonstrategicAnnual Global Wound Management Webinar collaboration with King's College Hospital London on wound care best practices and Hydrocyn Aqua product education, with over 300 participants from Europe and Asia.
Scale indicators13 records
Recent moves9 records
Expansion highlights6 records
Bactiguard competitors and assessment
Company assessmentBroad incumbents
- Hollister Incorporated: Privately held MedTech with ostomy, continence, and wound care products; comparable in wound care and continence categories where Bactiguard's catheter and HYDROCYN offerings compete.
- Smith+Nephew: Diversified MedTech with substantial wound management franchise (Allevyn, PICO) and orthopedics; an established incumbent overlapping Bactiguard's wound care and orthopedic coating markets.
- Coloplast: Global leader in ostomy, continence, and wound care, with significant catheter business; competes broadly with Bactiguard's urology catheter license partners and overlaps in advanced wound care.
- Mölnlycke Health Care: Private global MedTech focused on wound care (Mepilex, Avance) and surgical solutions; comparable wound management competitor with stronger direct commercial reach than Bactiguard.
- Convatec: Large medical products company with wound care, ostomy, and continence portfolios; competes with Bactiguard's HYDROCYN aqua wound management products across hospital and homecare channels.
Direct peers
- Covalon Technologies: Specialist antimicrobial coating company developing infection-prevention technologies for medical devices and wound care, overlapping with Bactiguard's BIP coating and HYDROCYN wound care platforms.
- Sciessent (formerly Agion): Provider of silver-based antimicrobial technologies licensed into medical devices and consumer products; competes with Bactiguard for MedTech license partnerships in catheter and device coating applications.
- Teleflex: Global MedTech company with a portfolio of coated urinary catheters and endotracheal tubes (including Arrow and Rusch brands); competes directly with Bactiguard's licensed catheter franchise via silver and antimicrobial-coated offerings.
Others
- Becton Dickinson (BD): Bactiguard's largest license partner for Foley catheters; while not a competitor in the coating technology itself, BD's own coating R&D and pricing decisions materially affect Bactiguard's royalty trajectory.
- DSM Biomedical (Royal DSM): Supplier of biocompatible coatings and materials used on medical devices; adjacent enabling technology provider with overlapping customer base of catheter and implant manufacturers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Bactiguard social profiles
Digital presenceBactiguard financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bactiguard leadership team
Management profileNumber of profiles
Profiles8 records
Bactiguard funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bactiguard M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bactiguard
What does Bactiguard do?
Bactiguard develops and licenses its proprietary Bactiguard Infection Protection (BIP) technology—an ultra-thin noble metal alloy coating that prevents microbial adhesion and biofilm formation on medical devices through a galvanic effect—to global MedTech partners for integration into their branded devices including Foley catheters, central venous catheters, endotracheal tubes, and orthopedic trauma implants. The company also distributes a wound management portfolio (HYDROCYN aqua hypochlorous acid wound care products and surgical sutures) through regional distributors to healthcare providers.
Is Bactiguard a public or private company?
Bactiguard is a public company. It is classified as public and is currently operating.
When was Bactiguard founded?
Bactiguard was founded in 2005. It employs 101 to 250 people.
Where is Bactiguard based?
Bactiguard is headquartered in Tullinge, Sweden, in the Europe region.
How does Bactiguard make money?
Four revenue lines are on record. License Partnerships - Application Development is the primary driver. The others are license Partnerships - Exclusivity, license Partnerships - Full License and wound Management Products.
Who are Bactiguard's main competitors?
Broad incumbents on record are Hollister Incorporated, Smith+Nephew, Coloplast, Mölnlycke Health Care and Convatec. Direct peers are Covalon Technologies, Sciessent (formerly Agion) and Teleflex. Others are Becton Dickinson (BD) and DSM Biomedical (Royal DSM).
Does Bactiguard have an API?
No public API is recorded for Bactiguard.
What industry is Bactiguard in?
Bactiguard's product category is Medical Device Infection Prevention. Its primary akta.pro industry code is IMALAIAA, Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules). Its NAICS code is 339113 and its SIC code is 3841.